IP Library Granted Patent US 7,473,543
Granted Patent B2
US 7,473,543 · App. 11/539,276 · Granted Jan 6, 2009

Thrombin compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,473,543
App. No.
11/539,276
Granted
Jan 6, 2009
Kind
B2
Abstract

Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 mM CaCl 2 , 0.03% to 1% (w/v) of a surfactant or high-molecular-weight polyethylene glycol, and a physiologically acceptable buffer, or may be in lyophilized form.

Claims (49)

1. A lyophilized composition, from a formulation that is pre-lyophilized consisting essentially of:

0.1 mg/mL to 5.0 mg/mL thrombin;

2% to 4% (w/v) sucrose;

3.5% to 5% (w/v) mannitol;

50 mM to 300 mM NaCl;

0-5 mM CaCl 2 ;

0.03% to 1% (w/v) of a surfactant or high-molecular-weight polyethylene glycol; and

a physiologically acceptable buffer, in aqueous solution at pH 5.7-7.4, wherein concentration of the buffer is selected to provide approximately physiological pH upon application of the composition in a surgical setting and wherein the ratio of mannitol:sucrose is greater than 1:1 but not greater than 2.5:1 (w/w).

2. The lyophilized composition of claim 1 wherein the ratio of mannitol to sucrose is 1.33:1 (w/w).

3. The lyophilized composition of claim 1 wherein the molar ratio of sucrose:thrombin is at least 700:1.

4. The lyophilized composition of claim 1 wherein the molar ratio of sucrose:thrombin is at least 2000:1.

5. The lyophilized composition of claim 1 wherein the thrombin is human thrombin.

6. The lyophilized composition of claim 1 wherein the thrombin is recombinant human thrombin.

7. The lyophilized composition of claim 1 wherein the thrombin concentration is 0.5-3.0 mg/ml.

8. The lyophilized composition of claim 1 wherein the thrombin concentration is 1 mg/ml.

9. The lyophilized composition of claim 1 wherein the sucrose concentration is 3% (w/v).

10. The lyophilized composition of claim 1 wherein the mannitol concentration is 4% (w/v).

11. The lyophilized composition of claim 1 wherein the sucrose concentration is 3% (w/v) and the mannitol concentration is 4% (w/v).

12. The lyophilized composition of claim 1 wherein the surfactant or high-molecular-weight polyethylene glycol is PEG 3350.

13. The lyophilized composition of claim 12 wherein the concentration of PEG 3350 is 0.1% (w/v).

14. The lyophilized composition of claim 1 wherein the pH is 6.0.

15. The lyophilized composition of claim 1 wherein the buffer is selected from the group consisting of histidine, citrate, phosphate, Tris, and succinate buffers.

16. The lyophilized composition of claim 1 wherein the buffer is histidine buffer.

17. The lyophilized composition of claim 16 wherein the histidine buffer concentration is 2.0-10 mM.

18. The lyophilized composition of claim 1 wherein the buffer is 5 mM histidine pH 6.0.

19. The lyophilized composition of claim 1 , wherein said formulation that is pre-lyophilized consists essentially of:

0.1 mg/mL to 5.0 mg/mL thrombin;

2% to 4% (w/v) sucrose;

3.5% to 5% (w/v) mannitol;

100 mM to 200 mM NaCl;

1 mM to 5 mM CaCl 2 ;

0.03% to 1% (w/v) PEG3350; and

2 mM to 10 mM histidine in aqueous solution at pH 5.5-6.5, wherein the ratio of mannitol:sucrose is greater than 1:1 but not greater than 2.5:1 (w/w).

20. The lyophilized composition of claim 19 , wherein said formulation that is pre-lyophilized consists essentially of:

1 mg/ml thrombin;

3% (w/v) sucrose;

4% (w/v) mannitol;

4 mM CaCl 2 ;

0.1% (w/v) PEG3350;

150 mM NaCl; and

5 mM histidine

at pH 6.0.

21. The lyophilized composition of claim 1 contained in a sealed container having a label affixed to an exterior surface thereof.

22. The lyophilized composition of claim 21 , which contains from 2,500 to 20,000 NIH units of thrombin.

23. A kit comprising the lyophilized composition of claim 21 and a second sealed container containing a diluent.

24. The kit of claim 23 wherein the diluent is normal saline.

25. The lyophilized composition of claim 1 wherein the ratio of mannitol to sucrose is 1.33:1 (w/w) and the concentration of sodium chloride is 75 mM to 250 mM.

26. The lyophilized composition of claim 1 wherein the ratio of mannitol to sucrose is 1.33:1 (w/w) and the concentration of sodium chloride is 100 mM to 200 mM.

27. The lyophilized composition of claim 1 wherein the ratio of mannitol to sucrose is 1.33:1 (w/w) and the concentration of sodium chloride is 150 mM.

Assignments (9)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: JIANG, SHAN; SENDEROFF, RICHARD I.; MEYER, JEFFREY D.
To: ZYMOGENETICS, INC.
Reel/Frame 045896/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SIGNATORY PAGES ON SUPPORTING DOCUMENT PREVIOUSLY RECORDED AT REEL: 043723 FRAME: 0478. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT. Recorded Oct 3, 2017
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 044570/0091 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 28, 2017
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043723/0478 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 28, 2017
From: THE MEDICINES COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 043723/0188 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2015
From: ZYMOGENETICS, LLC
To: THE MEDICINES COMPANY
Reel/Frame 035988/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2012
From: ZYMOGENETICS, INC.
To: ZYMOGENETICS, LLC
Reel/Frame 029406/0917 →